������

Abstract

Introduction: Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1–3% of the white population. Although two incidence peaks have been suggested (in adolescence and adulthood), the onset may occur at any age, including childhood (1). Guidelines for pediatric psoriasis treatment are lacking due to side effects of therapies approved for treatment in adult patients. In this study we show that the treatment of psoriasis-affected children with Avian Immunologically Active Proteins (PI-2A) obtained using our patented technology under Romanian brands IMUNOINSTANT and IMUNOVIP (2-4) was followed by impressive resolution of clinical symptoms without reported side effects. PI-2A are a novel class of biological agents that target specific mediators of inflammation as well as antimicrobial resistant (AMR) microorganisms. Multiple studies have confirmed their efficacy in the treatment of psoriasis in adults (3). “Standard” PI-2A contain antibodies against a panel of 22 microbial antigens; they are formulated as sterile solution, sterile spray, granules, ointments, healing oily liquid, healing granules, healing tablets with easily adsorbable collagen VII, sterile yolk suspension. “Personalized” PI-2A are prepared similarly from pathological materials taken from psoriasis plaques of individual patients Study design: 15 children aged 3 to 12 years presenting severe psoriasis vulgaris were treated with “standard” PI-2A formulated as oral preparations (sterile solution, granules) and topic preparations (healing oily liquid, sterile yolk suspension) during a 3 months session. Subjects were excluded if presenting history of allergic reaction to egg-derived products. Evaluated parameters were: severity of skin lesions, presence and evolution of fingernail pitting. Results: The evolution of skin and fingernail lesions was favourable for the entire group of studied subjects (Figure 1 shows two representative cases). There were no reports of intolerance or adverse reactions to the oral and topic use of PI-2A. Conclusion: PI-2A are an important too in the treatment of pediatric psoriasis. Recent Publications 1. Napolitano M, Megna M, Balato A, et al. Systemic Treatment of Pediatric Psoriasis: A Review. Dermatology and Therapy. 2016; 6(2): 125-142. 2. Pătrașcu Ionel Victor, Composition and Method for Preparing and Evaluating a Complex Immunogen Named I-spga Meant to Produce Immunologically Active Proteins (PIA). Patent Request A 00340 dated 06.06.2017. 3. Pătrașcu Ionel Victor, MVD, PhD. Active immunity by passive immunity. I-spga as a new Immunogen. A Modest Contribution to the Fight Against the Antimicrobial Resistance. SDG Lab, Davos, January 24, 2018; World Economic Forum Annual Meeting 23-26 January 2018, Davos-Klosters, Switzerland 4. Patrascu I.V., Chiurciu V., Chiurciu C., Sima L., Mihai I., The production and use of personalized hiperimune egg [evopach] in the treatment of psoriasis, OSIM, Patent no. A/00735- 16.10.2015.

Biography

Ionel Victor Pătraşcu MVD, PhD president of Activeimmunity, born on February 7, 1937. Graduated in Veterinary Medicine in Bucharest in 1963. Researcher in the field of virusology at Pasteur Institute in Bucharest. Made different specializations in the field of avian and human oncogenic viruses at Houghton Poultry Research Station, Huntington, England, at Friedrich-Loeffler- Institut, Celle, Institute of Animal Pathology in Rotherdam, Netherlands, Cornell University Ithaca NY and Athens University, Athens, GA. USA.In 1971 discovered to extract Fc 126 cell associated as cell free in SPGA and allowed to freeze-dry vaccine anti Marek disease lymphoma. He made the first research Center in the world at Voluntari, Romania, called Avian Tumor Viruses Lab, where specialists from England, U.S., France, Bulgaria, the German Democratic Republic, Hungary, the USSR, and China came to do studies in the period of the Iron Curtain and communist politics from Moscow. In 1989 discovered the largest outbreak in the world of HIV infection and AIDS in children in Romania.Studied antibiotic resistance of microorganisms and made first immunogen I-PC2 used biological preclinical and clinical human studies and the second generation of immunogen I-spga that was managed to prepare IMUNOVIP able to react specifically with superbugs infection by oral treatment of antibiotic-resitant urinary tract infections in women. During 1965-2017 he dealt with the training of specialists who are now valuable researchers, professors and academics.

E-mail: patrascu_john@yahoo.com